VERAXA Biotech (NASDAQ: VRXA), a biotechnology company focused on designing novel cancer therapies, has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer. The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development. VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics.
According to the company, Dr. Erkel previously served as Vice President of Research & Development, where he helped oversee development of VERAXA’s antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company’s BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward clinical testing. The appointment reinforces VERAXA’s focus on advancing its proprietary technology as it prepares its lead oncology programs for clinical development.
Recent regulatory feedback from Germany’s Paul-Ehrlich-Institute has provided additional clarity for development of the company’s lead BiTAC(R)-TCE program. This guidance is a critical step as VERAXA seeks to move its most advanced candidate into clinical trials. Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity.
VERAXA’s BiTAC(R) platform is designed to generate conditionally active T-cell engagers that may offer improved tumor targeting and reduced off-tissue toxicity compared to conventional bispecific antibodies. The company is also exploring bispecific antibody-drug conjugates (ADCs) and other engineered antibody formats to address multiple cancer targets. Dr. Erkel’s background in antibody therapeutics is expected to accelerate these programs.
The full terms of use and disclaimers are available on the InvestorBrandNetwork website. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These factors are detailed in the company’s filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
